

Remarks/Arguments

Applicants have amended the specification to provide the priority claim. The claims have been amended to remove multiple dependencies, correct certain typographical errors and to otherwise place the claims in an appropriate U.S. format. Specifically:


- Claim 1 has been amended to correct a typographical error in the spelling of "substituents" and the spelling of phosphonooxy in R¹⁰ has been corrected;
- Claim 4 has been amended to correct a typographical error and to remove the multiple dependency;
- Claim 5 has been amended to remove the multiple dependency and the spelling of phosphhonooxy has been corrected;
- Claims 6-9 inclusive have been amended to remove the multiple dependencies;
- Claim 10 has been amended to correct the multiple dependency;
- Claims 11-14 have been cancelled;
- Claims 15 and 16 have been amended to make the language consistent with other claims;
- Claim 17 has been amended to make the language consistent with other claims and to correct a couple of typographical errors, "substitutent" has been replaced by "substituted" in two occurrences, and "and'or" has been replaced with "and/or";
- Claim 18 has been added, this is based on original claim 13;
- Claim 19 has been added, this is based on original claim 1 incorporating the subject matter of claims 2, 4, 5, 6, 7 and 8;
- Claim 20 has been added, basis for this claim is to be found on page 11 line 30 to page 12 line 12;
- Claim 21 has been added, basis for this claim is to be found on page 12 line 26 to page 13 line 7;
- Claim 22 has been added, basis for this claim is to be found on page 13 line 24 to page 14 line 9;
- Claim 23 has been added, basis for this claim is to be found on page 14 line 29 to page 15 line 15, the values of R⁸ and R⁹ originally recited in the description have been omitted from this claim because they are superfluous; and
- Claim 24 has been added, this is based on original claim 10.

No new matter has been added by these amendments and the above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100937 1P-US.

Respectfully submitted,



Name: Lucy Padget
Dated: June 17, 2005
Reg. No.: Limited Recognition
Phone No.: 781-839-4182
Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 01760